Drugs / NNC0582-0001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05624580 | Nov 2022 → Oct 2025 | — | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0582-0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05624580 ↗ |
| Route | Subcutaneous | “subcutaneous NNC0582-0001” NCT05624580 ↗ |